RESEARCH TRIANGLE PARK – An RTP based drug development firm backed by a Bill Gates-linked foundation has raised more than $6 million as it continues to develop an Alzheimer’s treatment.
T3D Therapeutics disclosed the new funding in an SEC filing. The company, launched in 2013, says it has embraced a “transformational approach to treating Alzheimer’s and other neurodegenerative diseases.”
In 2020 the company received a $740,000 grant from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program.
Its lead compound is currently in a Phase 2 clinical trial.
The company received funding from 23 investors, according to the filing. It hopes to raise $7.5 million.
T3D raised $15 million in 2019 and $6 million in 2018.
Bill Gates, Alzheimer’s Association provide $740K grant to RTP startup
